scholarly journals Gastrointestinal Lymphomas: Entities and Mimics

2012 ◽  
Vol 136 (8) ◽  
pp. 865-870 ◽  
Author(s):  
Lauren B. Smith ◽  
Scott R. Owens

The gastrointestinal tract is the most common extranodal site of lymphoma involvement. Although B-cell lymphomas are by far the most frequent type found in this location, gastrointestinal lymphomas are a diverse group of neoplasms, many of which are characterized by distinctive clinicopathologic settings. Diffuse large B-cell lymphoma and marginal-zone lymphoma of mucosa-associated lymphoid tissue are commonly encountered, but other less-common entities can pose diagnostic challenges, mimicking both benign, reactive conditions and each other. We describe several different lymphoma subtypes, with a focus on frequently encountered challenges in differential diagnosis.

Piel ◽  
2017 ◽  
Vol 32 (5) ◽  
pp. 314-316
Author(s):  
Carolina Areán ◽  
Alicia Córdoba ◽  
Juan García ◽  
Amaia Larumbe

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1589-1589 ◽  
Author(s):  
Miguel Alcoceba ◽  
Elena Sebastián ◽  
Ana Balanzategui ◽  
Luis Marín ◽  
Santiago Montes-Moreno ◽  
...  

Abstract Abstract 1589 Introduction: Acquired potentially N-glycosylation sites are produced by somatic hypermutation (SHM) in the immunoglobulin (Ig) variable region. This phenomenon is produced in ∼9% of normal B-cells and seems to be related to certain B-cell lymphoproliferative disorders (B-LPDs) such as follicular lymphoma (FL, 79%), endemic Burkitt lymphoma (BL, 82%) and diffuse large B-cell lymphoma (DLBCL, 41%). These data suggest that new potential N-glycosylation sites could be related to germinal center B (GCB)-LPDs. By contrast, in other B-LPDs, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), MALT lymphoma, Waldenström macroglobulinemia (WM) or multiple myeloma (MM), these modifications have not been analyzed in deep. Aims: To evaluate the acquisition of potential N-glycosylation sites in B-LPDs, including immunohystochemical DLBCL subtypes (GCB and non-GCB) and specific non-GCB-LPDs, such as hairy cell leukemia (HCL), splenic marginal-zone lymphoma (SMZL), CLL, MCL, ocular extranodal marginal zone lymphoma (OAEMZL), MM and WM. Patients: A total of 953 sequences (203 from our group and 750 previously published sequences) of B-LPDs were included. Diagnosis distribution was as follows: DLBCL (n=235), MCL (n=235), CLL (n=166), MM (n=96), OAEMZL (n=82), SMZL (n=68), WM (n=38) and HCL (n=33). Methods: Acquired N-glycosylation sites were counted according to the sequence Asn-X-Ser/Thr, where X could be any amino acid except Pro. Natural motifs in germline sequences of IGHV1–08, IGHV4–34 e IGHV-5a were not considered. Fisher test was used to perform comparisons between groups. To distinguish DLBCL biological subtypes (GCB and non-GCB DLBCL), Hans' algorithm was used. Results: A total of 83 out of the 235 DLBCL cases acquired at least a new N-glycosylation site, a higher value than in normal B-cells (35% vs. 9%, p<0.0001). Higher incidence of these motifs in the group of GCB as compared to non-GCB DLBCL were observed (52% vs. 20%, p<0.0001). Those cases diagnosed of HCL, CLL, MCL, MM, WM, OAEMZL and SMZL presented a reduced number of new N-glycosylation sites, showing similar values than normal B-cells (range 3–18%, p=ns). Conclusions: We described for the first time the pattern of N-glycosylation in HCL, SMZL, OAEMZL and in the immunohystochemical DLBCL subtypes, where the GCB-DLBCL showed a higher number of new N-glycosylation sites with respect to non-GCB DLBCL and other non-GCB-LPDs. The presence of novel N-glycosylation sites in FL, BL and in GCB-DLBCL strongly suggests that these motifs are characteristic of the germinal center B-LPDs. Disclosures: No relevant conflicts of interest to declare.


2018 ◽  
Vol 6 (12) ◽  
pp. 2341-2346 ◽  
Author(s):  
Claire Auditeau ◽  
Olivier Lambotte ◽  
Joffrey Feriel ◽  
Thierry Lazure ◽  
Ali Turhan ◽  
...  

2021 ◽  
Author(s):  
Yaqin Xia ◽  
Jurui Ge ◽  
Zhenchang Sun ◽  
Feifei Nan ◽  
Wenjuan Wan ◽  
...  

Abstract Background: CD5 expression in diffuse large B-cell lymphoma has a poor prognosis but the prognostic value of CD5 expression in marginal zone lymphoma is undefined. Methods: Clinicopathological features, survival outcomes, and prognostic implications of marginal zone lymphoma were retrospectively analyzed in 204 patients. We classified patients into (i) CD5-positive marginal zone lymphoma (ii) CD5-negative marginal zone Lymphoma, Fisher's exact test was used to compare the CD5-positive and CD5-negative marginal zone lymphoma. Progression-free survival (PFS) and overall survival (OS) curves were summarized by Kaplan-Meier method and compared using the log-rank test, The Cox proportional hazard regression model was used for univariate and multivariate analyses. Results: CD5 expression is rare in marginal zone lymphoma, of 204 patients, only 48 (23.53%) had CD5-positive. Due to the characterized of slow growth and locally aggressive nature, the prognosis is favorable after treatment. at the end of the followup 179 patients were still alive,163 patients never progressed. The 5-year PFS and OS rates for marginal zone lymphoma were 65.10% and 77.30% respectively, the 5-year PFS and OS rates for CD5-positive marginal zone lymphoma were 64.80% and 84.10%, there is no significant difference between CD5-positive and CD5-negative ( P =0.829, P =0.521). Diffuse large B-cell lymphoma (DLBCL) transformation was pathologically indicated in 6 patients, of which 5(83.33%) patients were CD5-positive marginal zone lymphoma. Conclusion: CD5 expression in marginal zone lymphoma is not independently prognostic for PFS and OS. But CD5-positive marginal zone lymphoma seems more likely to transformation to diffuse large B-cell lymphoma.


2019 ◽  
Vol 215 (1) ◽  
pp. 222-228 ◽  
Author(s):  
Andrej Belančić ◽  
Luka Vranić ◽  
Ivan Ševeljević ◽  
Ita Hadžisejdić ◽  
Antica Duletić Načinović ◽  
...  

2006 ◽  
Vol 38 (3-4) ◽  
pp. 431-437 ◽  
Author(s):  
A. Canelhas ◽  
E. Compérat ◽  
A. Le Tourneau ◽  
T. Molina ◽  
M. Ramos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document